| Primary |
| Pulmonary Arterial Hypertension |
93.8% |
| Pulmonary Hypertension |
1.8% |
| Portopulmonary Hypertension |
1.1% |
| Product Used For Unknown Indication |
0.6% |
| Pain |
0.4% |
| Polyuria |
0.4% |
| Bronchospasm |
0.2% |
| Cardiac Failure |
0.2% |
| Maternal Exposure During Pregnancy |
0.2% |
| Nasal Congestion |
0.2% |
| Prophylaxis Against Diarrhoea |
0.2% |
| Prophylaxis Of Nausea And Vomiting |
0.2% |
| Pulmonary Arterial Pressure Decreased |
0.2% |
| Anticoagulant Therapy |
0.1% |
| Antiplatelet Therapy |
0.1% |
| Blood Culture Positive |
0.1% |
| Cardiac Fibrillation |
0.1% |
| Crest Syndrome |
0.1% |
| Depression |
0.1% |
| Digital Ulcer |
0.1% |
|
| Death |
21.4% |
| Pneumonia |
12.5% |
| Dyspnoea |
11.5% |
| Diarrhoea |
5.1% |
| Nausea |
5.1% |
| Pulmonary Arterial Hypertension |
3.7% |
| Vomiting |
3.7% |
| Fluid Retention |
3.4% |
| Pyrexia |
3.4% |
| Dizziness |
3.1% |
| Gastrointestinal Haemorrhage |
3.1% |
| Thrombocytopenia |
3.1% |
| Device Related Infection |
2.7% |
| Fatigue |
2.7% |
| Headache |
2.7% |
| Infection |
2.7% |
| Pain In Jaw |
2.7% |
| Right Ventricular Failure |
2.7% |
| Condition Aggravated |
2.4% |
| Hypotension |
2.4% |
|
| Secondary |
| Pulmonary Arterial Hypertension |
81.1% |
| Pulmonary Hypertension |
8.4% |
| Product Used For Unknown Indication |
1.7% |
| Drug Use For Unknown Indication |
1.5% |
| Portopulmonary Hypertension |
1.5% |
| Connective Tissue Disorder |
0.7% |
| Ill-defined Disorder |
0.7% |
| Sepsis |
0.7% |
| Maternal Exposure During Pregnancy |
0.5% |
| Prophylaxis |
0.5% |
| Nausea |
0.4% |
| Pain |
0.4% |
| Vasodilation Procedure |
0.4% |
| Drug Exposure During Pregnancy |
0.2% |
| Iron Deficiency |
0.2% |
| Right Ventricular Failure |
0.2% |
| Sarcoidosis |
0.2% |
| Gastrointestinal Disorder |
0.1% |
| Hypertension |
0.1% |
| Hypokalaemia |
0.1% |
|
| Dyspnoea |
10.5% |
| Condition Aggravated |
9.4% |
| Diarrhoea |
8.2% |
| Anaemia |
7.0% |
| Right Ventricular Failure |
5.8% |
| Medical Device Complication |
5.3% |
| Pulmonary Arterial Hypertension |
5.3% |
| Ventricular Tachycardia |
4.7% |
| Mental Disorder |
4.1% |
| Nausea |
4.1% |
| Syncope |
4.1% |
| Device Related Infection |
3.5% |
| Dizziness |
3.5% |
| Fatigue |
3.5% |
| Gastrointestinal Haemorrhage |
3.5% |
| Lung Transplant |
3.5% |
| Malaise |
3.5% |
| Pain In Jaw |
3.5% |
| Pneumonia |
3.5% |
| Therapy Regimen Changed |
3.5% |
|
| Concomitant |
| Product Used For Unknown Indication |
35.6% |
| Drug Use For Unknown Indication |
30.4% |
| Pulmonary Arterial Hypertension |
12.9% |
| Pulmonary Hypertension |
7.6% |
| Diuretic Therapy |
1.4% |
| Prophylaxis |
1.3% |
| Catheterisation Cardiac |
1.0% |
| Pain |
1.0% |
| Respiratory Disorder |
1.0% |
| Surgery |
1.0% |
| Nausea |
0.9% |
| Septic Shock |
0.9% |
| Continuous Haemodiafiltration |
0.8% |
| Gastrooesophageal Reflux Disease |
0.8% |
| Intravenous Catheter Management |
0.8% |
| Anticoagulant Therapy |
0.7% |
| Coronary Artery Bypass |
0.7% |
| Chronic Obstructive Pulmonary Disease |
0.6% |
| Scleroderma |
0.6% |
| Anaesthesia |
0.5% |
|
| Death |
12.9% |
| Dyspnoea |
7.9% |
| Pulmonary Hypertension |
7.9% |
| Right Ventricular Failure |
7.9% |
| Thrombocytopenia |
7.9% |
| Vomiting |
7.9% |
| Ventricular Tachycardia |
6.9% |
| Pulmonary Arterial Hypertension |
5.0% |
| Pyrexia |
5.0% |
| Renal Impairment |
4.0% |
| Abdominal Pain |
3.0% |
| Blood Bilirubin Increased |
3.0% |
| Blood Potassium Decreased |
3.0% |
| Central Venous Catheterisation |
3.0% |
| Haemoptysis |
3.0% |
| Hepatic Function Abnormal |
3.0% |
| Syncope |
3.0% |
| Anaemia |
2.0% |
| Aspartate Aminotransferase Increased |
2.0% |
| Biopsy Lung |
2.0% |
|
